Acticor Biotech SAS (ALACT.PA)
| Previous close | 0.8600 |
| Open | 0.8800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.5700 - 0.8900 |
| 52-week range | 0.2200 - 5.3200 |
| Volume | |
| Avg. volume | 37,942 |
| Market cap | 9.337M |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Acticor Biotech appoints François Guillet as Chief Financial Officer
PARIS, October 14, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects.
- Business Wire
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction
PARIS, October 11, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction.
- Business Wire
Acticor Biotech: Extension of the Receivership Procedure
PARIS, October 03, 2024--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces that the Paris Commercial Court has today pronounced the extension of the company's receivership proceedings.
